美国性传染感染和阴道炎 PCR 检测市场规模、份额、趋势分析报告：疾病状况、检测类型、最终用途、细分市场预测，2025-2030 年

美国性传染感染和阴道炎 PCR 检测市场趋势：

预计 2024 年美国性传染感染和阴道炎 PCR 检测市场规模将达到 2.4072 亿美元，2025 年至 2030 年的复合年增长率为 8.2%。

性行为感染盛行率的不断上升和患者意识的不断提高推动了对先进诊断工具的需求。美国疾病管制与预防中心（CDC）每年持续报告数百万例新的性传染感染病例，其中最常见的是披衣菌感染、淋病和滴虫病。感染疾病的增加迫切需要早期且准确的检测方法。聚合酵素链锁反应（PCR）检测具有高灵敏度和特异性，是传统诊断方法的可靠替代方法。由于患者和临床医生优先考虑快速且准确的结果，PCR 检测在医疗设施更便利、检测频率更高的都市区中广受欢迎，这进一步推动了市场扩张。与筛检相关的耻辱感的逐渐减少也在鼓励及时诊断方面发挥关键作用。

将PCR检测纳入诊所和医院的常规妇科和性卫生评估也是一个主要驱动因素。许多医疗保健提供者现在建议高风险族群定期进行检测，这增加了对基于PCR的解决方案的需求。就地检验和家用样本采集试剂套件的日益流行，使得性传染感染和阴道炎的检测更加便捷。这些创新支持早期发现，并减少了与诊所内检测相关的障碍。因此，诊断实验室和生物技术公司正在投资开发针对美国市场的易于使用的快速PCR套件。诊断公司和远端医疗平台之间日益增长的伙伴关係关係扩大了PCR检测服务的可近性。私人保险公司和雇主不断增加的医疗保健支出也支持了先进诊断技术的广泛应用。

多重PCR平台的技术进步正在提高性传染感染和阴道炎检测的效率。这些创新技术能够同时检测单一样本中的多种病原体，从而降低成本并缩短检测时间。这些技术进步对于管理性传染感染患者中常见的合併感染尤其有效。此外，正在进行的微流体PCR设备和样品製备自动化研究将提高实验室的通量。这项进步将惠及面临日益增长的检测量的大型诊断网络和美国独立实验室。竞争格局也不断演变，领先的公司正在推出针对难以检测病原体的新型PCR检测方法。随着此类先进诊断方法的普及，整个市场的收益预计在2030年之前持续成长。

滴虫病仍然是一个值得关注的问题，尤其对女性而言，最近的研究强调了它与不良妊娠结局的关係，这鼓励了分子检测的广泛应用。单纯疱疹病毒（HSV-1 和 HSV-2）由于其反覆发作和无症状性排放而继续被广泛检测，用于快速诊断的新型快速 PCR 检测已获得 FDA核准。人类乳突病毒 (HPV) 检测对于识别与子宫颈癌和其他癌症相关的高风险病毒株至关重要，正如采用现代 FDA核准的HPV 检测（如罗氏的 Cobas HPV 检测）进行早期癌症筛检所见。梅毒和其他性传染感染虽然不太常见，但包含在多重检测组中以确保全面筛检和早期疗育，多重 PCR 检测组最近已在临床试验中得到检验，以提高灵敏度。

目录

第一章调查方法与范围

第二章执行摘要

第 3 章美国性传染感染和阴道炎 PCR 检测市场变数、趋势和范围

• 市场展望
• 市场动态
  • 市场驱动因素分析
  • 市场限制因素分析
• 商业环境分析
  • 产业分析-波特五力分析
  • PESTLE分析

第四章美国性传染感染与阴道炎 PCR 检测市场：病理生理学商业分析

• 2024年及2030年的疾病市场占有率
• 疾病细分仪表板
• 市场规模、预测与趋势分析（依疾病状况，2018-2030 年）
• 性行为感染感染（STI）
• 阴道感染疾病

第五章美国性传染感染与阴道炎 PCR 检测市场：检测类型业务分析

• 2024 年和 2030 年测试类型市场占有率
• 考试类型细分仪表板
• 按测试类型分類的市场规模、预测和趋势分析（2018-2030 年）
• STI PCR 检测试剂盒
• 阴道炎PCR检测试剂盒

第六章美国性传染感染和阴道炎 PCR 检测市场：最终用途业务分析

• 2024 年及 2030 年最终用途市场占有率
• 最终用途细分仪表板
• 按最终用途分類的市场规模、预测和趋势分析（2018-2030 年）
• 医院和诊所
• 诊断实验室
• 居家照护/居家检测
• 其他的

第七章 竞争态势

• 参与者概览
• 企业市场分析
• 公司分类
• 战略地图
• 公司简介/上市公司
  • Becton, Dickinson and Company（BD）
  • F. Hoffmann-La Roche Ltd.
  • Hologic, Inc.
  • Abbott
  • Danaher Corporation（Cepheid）
  • Seegene Inc.
  • bioMerieux（BioFire Diagnostics）
  • QIAGEN
  • Thermo Fisher Scientific, Inc.
  • DiaSorin SpA（Luminex）
  • Sansure Biotech Inc
  • R-Biopharm AG
  • altona Diagnostics GmbH
  • CERTEST BIOTEC.

U.S. STI & Vaginitis PCR Testing Market Trends:

The U.S. STI & vaginitis PCR testing market size was estimated at USD 240.72 million in 2024 and is projected to grow at a CAGR of 8.2% from 2025 to 2030. The increasing prevalence of sexually transmitted infections and growing patient awareness are driving demand for advanced diagnostic tools. The Centers for Disease Control and Prevention (CDC) continues to report millions of new STI cases each year, with chlamydia, gonorrhea, and trichomoniasis among the most reported. This rise in infections has created a pressing need for early and accurate detection methods. Polymerase chain reaction (PCR) tests provide high sensitivity and specificity, offering a reliable alternative to traditional diagnostics. As patients and clinicians prioritize quick and accurate results, PCR testing is gaining widespread preference in urban populations, with better access to healthcare facilities and higher testing frequencies, further supporting market expansion. The gradual decline in stigma related to STI screening also plays a vital role in encouraging timely diagnosis.

The integration of PCR testing into routine gynecological and sexual health evaluations in clinics and hospitals is another key driver. Many healthcare providers now recommend regular testing for at-risk populations, enhancing demand for PCR-based solutions. The growing trend of point-of-care testing and at-home sample collection kits has made STI and vaginitis testing more convenient. These innovations support early detection and reduce barriers associated with clinic-based testing. As a result, diagnostic labs and biotech firms are investing in developing user-friendly, rapid PCR kits tailored for the U.S. market. Rising partnerships between diagnostic companies and telehealth platforms expand access to PCR testing services. Increased healthcare spending by private insurers and employers also supports wider adoption of advanced diagnostic technologies.

Technological advancements in multiplex PCR platforms are improving the efficiency of STI and vaginitis testing. These innovations allow the simultaneous detection of multiple pathogens from a single sample, reducing costs and turnaround time. Such developments are particularly valuable for managing co-infections, which are common among patients with STIs. Furthermore, ongoing research into microfluidic PCR devices and automated sample preparation enhances laboratory throughput. This progress benefits large diagnostic networks and independent U.S. labs facing rising testing volumes. The competitive landscape is also evolving, with leading players launching novel PCR assays targeting hard-to-detect organisms. As these advanced diagnostics become more accessible, the overall market will witness consistent revenue growth through 2030.

Trichomoniasis remains a significant concern, especially in women, with recent studies emphasizing its link to adverse pregnancy outcomes, prompting wider use of molecular testing. Herpes Simplex Virus (HSV-1 & HSV-2) continues to see widespread testing due to its recurrent nature and asymptomatic shedding, with new rapid PCR assays gaining FDA approval for quicker diagnosis. Human Papillomavirus (HPV) testing is essential for identifying high-risk strains linked to cervical and other cancers, as seen in the adoption of the latest FDA-approved HPV assays like Roche's Cobas HPV test for early cancer screening. Syphilis and other STIs, though less common, are included in multiplex panels to ensure comprehensive detection and early intervention, with multiplex PCR panels recently validated in clinical studies for improved sensitivity.

U.S. STI & Vaginitis PCR Testing Market Report Segmentation

This report forecasts country revenue growth and analyzes the latest industry trends in each sub-segment from 2018 to 2030. For this study, Grand View Research has segmented the U.S. STI & vaginitis PCR testing market report based on condition, test type, and end use.

• Condition Outlook (Revenue, USD Million, 2018 - 2030)
• Sexually Transmitted Infections (STIs)
  • Chlamydia
  • Gonorrhea
  • Trichomoniasis
  • Herpes Simplex Virus (HSV-1 & HSV-2)
  • Human Papillomavirus (HPV)
  • Syphilis
  • Other
• Vaginal Infections
  • Bacterial Vaginosis
  • Vulvovaginal Candidiasis
  • Others
• Test Type Outlook (Revenue, USD Million, 2018 - 2030)
• STI PCR Panels
• Vaginitis PCR Panels
• End Use Outlook (Revenue, USD Million, 2018 - 2030)
• Hospitals and Clinics
• Diagnostic Laboratories
• Homecare/At-home Testing
• Others

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Condition
  • 1.2.2. Test Type
  • 1.2.3. End Use
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. STI & Vaginitis PCR Testing Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis

Chapter 4. U.S. STI & Vaginitis PCR Testing Market: Condition Business Analysis

• 4.1. Condition Market Share, 2024 & 2030
• 4.2. Condition Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Condition, 2018 to 2030 (USD Million)
• 4.4. Sexually Transmitted Infections (STIs)
  • 4.4.1. Sexually Transmitted Infections (STIs) Market, 2018 - 2030 (USD Million)
  • 4.4.2. Chlamydia
    • 4.4.2.1. Chlamydia Market, 2018 - 2030 (USD Million)
  • 4.4.3. Gonorrhea
    • 4.4.3.1. Gonorrhea Market, 2018 - 2030 (USD Million)
  • 4.4.4. Trichomoniasis
    • 4.4.4.1. Trichomoniasis Market, 2018 - 2030 (USD Million)
  • 4.4.5. Herpes Simplex Virus (HSV-1 & HSV-2
    • 4.4.5.1. Herpes Simplex Virus (HSV-1 & HSV-2) Market, 2018 - 2030 (USD Million)
  • 4.4.6. Human Papillomavirus (HPV)
    • 4.4.6.1. Human Papillomavirus (HPV) Market, 2018 - 2030 (USD Million)
  • 4.4.7. Syphilis
    • 4.4.7.1. Syphilis Market, 2018 - 2030 (USD Million)
  • 4.4.8. Other
    • 4.4.8.1. Other Market, 2018 - 2030 (USD Million)
• 4.5. Vaginal Infections
  • 4.5.1. Vaginal Infections Market, 2018 - 2030 (USD Million)
  • 4.5.2. Bacterial Vaginosis
    • 4.5.2.1. Bacterial Vaginosis Market, 2018 - 2030 (USD Million)
  • 4.5.3. Vulvovaginal Candidiasis
    • 4.5.3.1. Vulvovaginal Candidiasis Market, 2018 - 2030 (USD Million)
  • 4.5.4. Others
    • 4.5.4.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. U.S. STI & Vaginitis PCR Testing Market: Test Type Business Analysis

• 5.1. Test Type Market Share, 2024 & 2030
• 5.2. Test Type Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Test Type, 2018 to 2030 (USD Million)
• 5.4. STI PCR Panels
  • 5.4.1. STI PCR Panels Market, 2018 - 2030 (USD Million)
• 5.5. Vaginitis PCR Panels
  • 5.5.1. Vaginitis PCR Panels Market, 2018 - 2030 (USD Million)

Chapter 6. U.S. STI & Vaginitis PCR Testing Market: End Use Business Analysis

• 6.1. End Use Market Share, 2024 & 2030
• 6.2. End Use Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 6.4. Hospitals and Clinics
  • 6.4.1. Hospitals and Clinics, 2018 - 2030 (USD Million)
• 6.5. Diagnostic Laboratories
  • 6.5.1. Diagnostic Laboratories Market, 2018 - 2030 (USD Million)
• 6.6. Homecare/At-home Testing
  • 6.6.1. Homecare/At-home Testing Market, 2018 - 2030 (USD Million)
• 6.7. Others
  • 6.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Participant Overview
• 7.2. Company Market Position Analysis
• 7.3. Company Categorization
• 7.4. Strategy Mapping
• 7.5. Company Profiles/Listing
  • 7.5.1. Becton, Dickinson and Company (BD)
    • 7.5.1.1. Overview
    • 7.5.1.2. Financial Performance
    • 7.5.1.3. Type Benchmarking
    • 7.5.1.4. Strategic Initiatives
  • 7.5.2. F. Hoffmann-La Roche Ltd.
    • 7.5.2.1. Overview
    • 7.5.2.2. Financial Performance
    • 7.5.2.3. Type Benchmarking
    • 7.5.2.4. Strategic Initiatives
  • 7.5.3. Hologic, Inc.
    • 7.5.3.1. Overview
    • 7.5.3.2. Financial Performance
    • 7.5.3.3. Type Benchmarking
    • 7.5.3.4. Strategic Initiatives
  • 7.5.4. Abbott
    • 7.5.4.1. Overview
    • 7.5.4.2. Financial Performance
    • 7.5.4.3. Type Benchmarking
    • 7.5.4.4. Strategic Initiatives
  • 7.5.5. Danaher Corporation (Cepheid)
    • 7.5.5.1. Overview
    • 7.5.5.2. Financial Performance
    • 7.5.5.3. Type Benchmarking
    • 7.5.5.4. Strategic Initiatives
  • 7.5.6. Seegene Inc.
    • 7.5.6.1. Overview
    • 7.5.6.2. Financial Performance
    • 7.5.6.3. Type Benchmarking
    • 7.5.6.4. Strategic Initiatives
  • 7.5.7. bioMerieux (BioFire Diagnostics)
    • 7.5.7.1. Overview
    • 7.5.7.2. Financial Performance
    • 7.5.7.3. Type Benchmarking
    • 7.5.7.4. Strategic Initiatives
  • 7.5.8. QIAGEN
    • 7.5.8.1. Overview
    • 7.5.8.2. Financial Performance
    • 7.5.8.3. Type Benchmarking
    • 7.5.8.4. Strategic Initiatives
  • 7.5.9. Thermo Fisher Scientific, Inc.
    • 7.5.9.1. Overview
    • 7.5.9.2. Financial Performance
    • 7.5.9.3. Type Benchmarking
    • 7.5.9.4. Strategic Initiatives
  • 7.5.10. DiaSorin S.p.A (Luminex)
    • 7.5.10.1. Overview
    • 7.5.10.2. Financial Performance
    • 7.5.10.3. Type Benchmarking
    • 7.5.10.4. Strategic Initiatives
  • 7.5.11. Sansure Biotech Inc
    • 7.5.11.1. Overview
    • 7.5.11.2. Financial Performance
    • 7.5.11.3. Type Benchmarking
    • 7.5.11.4. Strategic Initiatives
  • 7.5.12. R-Biopharm AG
    • 7.5.12.1. Overview
    • 7.5.12.2. Financial Performance
    • 7.5.12.3. Type Benchmarking
    • 7.5.12.4. Strategic Initiatives
  • 7.5.13. altona Diagnostics GmbH
    • 7.5.13.1. Overview
    • 7.5.13.2. Financial Performance
    • 7.5.13.3. Type Benchmarking
    • 7.5.13.4. Strategic Initiatives
  • 7.5.14. CERTEST BIOTEC.
    • 7.5.14.1. Overview
    • 7.5.14.2. Financial Performance
    • 7.5.14.3. Type Benchmarking
    • 7.5.14.4. Strategic Initiatives

List of Tables

• Table 1 List of secondary sources
• Table 2 List of abbreviations
• Table 3 U.S. STI & vaginitis PCR testing market, by condition, 2018 - 2030 (USD Million)
• Table 4 U.S. STI & vaginitis PCR testing market, by test type, 2018 - 2030 (USD Million)
• Table 5 U.S. STI & vaginitis PCR testing market, by end use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 U.S. STI & vaginitis PCR testing market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 Market formulation & validation
• Fig. 8 Market snapshot
• Fig. 9 Condition outlook (USD Million)
• Fig. 10 Test Type outlook (USD Million)
• Fig. 11 End Use outlook (USD Million)
• Fig. 12 Competitive landscape
• Fig. 13 U.S. STI & vaginitis PCR testing market dynamics
• Fig. 14 U.S. STI & vaginitis PCR testing market: Porter's five forces analysis
• Fig. 15 U.S. STI & vaginitis PCR testing market: PESTLE analysis
• Fig. 16 U.S. STI & vaginitis PCR testing market: Condition segment dashboard
• Fig. 17 U.S. STI & vaginitis PCR testing market: Condition market share analysis, 2024 & 2030
• Fig. 18 Sexually Transmitted Infections (STIs) market, 2018 - 2030 (USD Million)
• Fig. 19 Chlamydia market, 2018 - 2030 (USD Million)
• Fig. 20 Gonorrhea market, 2018 - 2030 (USD Million)
• Fig. 21 Trichomoniasis market, 2018 - 2030 (USD Million)
• Fig. 22 Herpes Simplex Virus (HSV-1 & HSV-2) market, 2018 - 2030 (USD Million)
• Fig. 23 Human Papillomavirus (HPV) market, 2018 - 2030 (USD Million)
• Fig. 24 Syphilis market, 2018 - 2030 (USD Million)
• Fig. 25 Other market, 2018 - 2030 (USD Million)
• Fig. 26 Vaginal infections market, 2018 - 2030 (USD Million)
• Fig. 27 Bacterial vaginosis market, 2018 - 2030 (USD Million)
• Fig. 28 Vulvovaginal candidiasis market, 2018 - 2030 (USD Million)
• Fig. 29 Others market, 2018 - 2030 (USD Million)
• Fig. 30 U.S. STI & vaginitis PCR testing market: Test Type segment dashboard
• Fig. 31 U.S. STI & vaginitis PCR testing market: Test Type market share analysis, 2024 & 2030
• Fig. 32 STI PCR panels market, 2018 - 2030 (USD Million)
• Fig. 33 Vaginitis PCR panels market, 2018 - 2030 (USD Million)
• Fig. 34 U.S. STI & vaginitis PCR testing market: End use segment dashboard
• Fig. 35 U.S. STI & vaginitis PCR testing market: End use market share analysis, 2024 & 2030
• Fig. 36 Hospitals and clinics market, 2018 - 2030 (USD Million)
• Fig. 37 Diagnostic laboratories market, 2018 - 2030 (USD Million)
• Fig. 38 Homecare/at-home testing market, 2018 - 2030 (USD Million)
• Fig. 39 Others market, 2018 - 2030 (USD Million)
• Fig. 40 Company categorization
• Fig. 41 Company market position analysis
• Fig. 42 Strategic framework